Suppr超能文献

相似文献

1
A targeted maximum likelihood estimator for two-stage designs.
Int J Biostat. 2011 Mar 11;7(1):17. doi: 10.2202/1557-4679.1217.
2
Collaborative double robust targeted maximum likelihood estimation.
Int J Biostat. 2010 May 17;6(1):Article 17. doi: 10.2202/1557-4679.1181.
3
The relative performance of targeted maximum likelihood estimators.
Int J Biostat. 2011;7(1). doi: 10.2202/1557-4679.1308. Epub 2011 Aug 17.
4
Double robust and efficient estimation of a prognostic model for events in the presence of dependent censoring.
Biostatistics. 2016 Jan;17(1):165-77. doi: 10.1093/biostatistics/kxv028. Epub 2015 Jul 29.
5
Double Robust Efficient Estimators of Longitudinal Treatment Effects: Comparative Performance in Simulations and a Case Study.
Int J Biostat. 2019 Feb 26;15(2):/j/ijb.2019.15.issue-2/ijb-2017-0054/ijb-2017-0054.xml. doi: 10.1515/ijb-2017-0054.
7
Best linear inverse probability weighted estimation for two-phase designs and missing covariate regression.
Stat Med. 2019 Jul 10;38(15):2783-2796. doi: 10.1002/sim.8141. Epub 2019 Mar 25.
8
Targeted maximum likelihood estimation in safety analysis.
J Clin Epidemiol. 2013 Aug;66(8 Suppl):S91-8. doi: 10.1016/j.jclinepi.2013.02.017.
9
Collaborative targeted maximum likelihood for time to event data.
Int J Biostat. 2010;6(1):Article 21. doi: 10.2202/1557-4679.1249.
10
A targeted maximum likelihood estimator of a causal effect on a bounded continuous outcome.
Int J Biostat. 2010;6(1):Article 26. doi: 10.2202/1557-4679.1260. Epub 2010 Aug 1.

引用本文的文献

1
A surrogate endpoint-based provisional approval causal roadmap, illustrated by vaccine development.
Biostatistics. 2024 Dec 31;26(1). doi: 10.1093/biostatistics/kxaf018.
2
Emulating Clinical Trials with the Mayo Clinic Platform: Cardiovascular Research Perspective.
medRxiv. 2025 Mar 24:2025.03.19.25324271. doi: 10.1101/2025.03.19.25324271.
4
Mediation model with a categorical exposure and a censored mediator with application to a genetic study.
PLoS One. 2021 Oct 12;16(10):e0257628. doi: 10.1371/journal.pone.0257628. eCollection 2021.
5
Post-randomization Biomarker Effect Modification Analysis in an HIV Vaccine Clinical Trial.
J Causal Inference. 2020;8(1):54-69. doi: 10.1515/jci-2019-0022. Epub 2020 Jul 25.
8
Designing a Study of Correlates of Risk for Ebola Vaccination.
Am J Epidemiol. 2020 Aug 1;189(8):747-754. doi: 10.1093/aje/kwaa001.
9
Considerations for outcome-dependent biased sampling in health databases.
Stat Med. 2019 Sep 30;38(22):4213-4215. doi: 10.1002/sim.8324.
10
Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials.
Stat Med. 2019 Oct 15;38(23):4503-4518. doi: 10.1002/sim.8310. Epub 2019 Jul 17.

本文引用的文献

2
Estimation based on case-control designs with known prevalence probability.
Int J Biostat. 2008;4(1):Article 17. doi: 10.2202/1557-4679.1114.
3
Targeted maximum likelihood based causal inference: Part I.
Int J Biostat. 2010;6(2):Article 2. doi: 10.2202/1557-4679.1211.
4
Collaborative targeted maximum likelihood for time to event data.
Int J Biostat. 2010;6(1):Article 21. doi: 10.2202/1557-4679.1249.
5
Targeted maximum likelihood estimation of the parameter of a marginal structural model.
Int J Biostat. 2010;6(2):Article 19. doi: 10.2202/1557-4679.1238. Epub 2010 Apr 15.
6
A targeted maximum likelihood estimator of a causal effect on a bounded continuous outcome.
Int J Biostat. 2010;6(1):Article 26. doi: 10.2202/1557-4679.1260. Epub 2010 Aug 1.
7
Simple optimal weighting of cases and controls in case-control studies.
Int J Biostat. 2008 Sep 29;4(1):Article 19. doi: 10.2202/1557-4679.1115.
8
Why match? Investigating matched case-control study designs with causal effect estimation.
Int J Biostat. 2009 Jan 6;5(1):Article 1. doi: 10.2202/1557-4679.1127.
9
Increasing power in randomized trials with right censored outcomes through covariate adjustment.
J Biopharm Stat. 2009 Nov;19(6):1099-131. doi: 10.1080/10543400903243017.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验